Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
06/10/2026 07:29
BRIEF-Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP Oct 6 (Reuters) - Mabion SA MABP.WA:
HELD PRE-IND TYPE B MEETING WITH U.S. FDA ON MABIONCD20 DEVELOPMENT PROGRAM FOR IMMUNE THROMBOCYTOPENIA (ITP)
MEETING WITH U.S. FDA INCLUDED DISCUSSION OF PRODUCT DEVELOPMENT STRATEGY, CMC AND CLINICAL DATA, REGULATORY PATHWAY WITH FDA
EXPECTS OFFICIAL FDA MEETING SUMMARY WITHIN 30 DAYS
Source text: ID:nEM6R4DhDa
Further company coverage: MABP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects